title: Canine Leishmania vaccines: still a long way to go.
abstract: Dogs are the main reservoir host for zoonotic visceral leishmaniasis, a sand fly-borne disease caused by Leishmania infantum. In endemic areas, "susceptible" dogs suffer from a severe disease characterized by chronic polymorphic viscerocutaneous signs that manifest several months from the exposure, whereas "resistant" dogs can remain subclinically infected for years or lifelong. The protective immune response to Leishmania is cell-mediated; for visceralizing Leishmania species a mixed T helper (Th)1/Th2 response with a dominant Th1 profile is required for protection. The activation of the adaptive immune system in naturally resistant dogs is revealed by parasite-specific lymphoproliferation, delayed-type hypersensitivity, the production of interferon-γ and tumour necrosis factor-α cytokines, and enhanced macrophage leishmanicidal activity via nitric oxide. Hence, an effective canine Leishmania vaccine should induce strong and long-lasting Th1-dominated immunity to control both infection progression and the parasite transmissibility via the vector. Preclinical research in rodent models has evaluated the efficacy of several categories of Leishmania antigens including killed parasites, cell purified fractions, parasite protein components or subunits, single or multiple chimeric recombinant proteins, plasmid DNA and viral particles encoding parasite virulence factors. Promising antigen(s)/adjuvant combinations from each of the above categories have also been tested in dogs; they mostly resulted in limited or no protection in Phase I-II studies (designed to test vaccine safety, immunogenicity and laboratory-induced protection) in which vaccinated dogs were challenged by the artificial intravenous injection of high-load L. infantum promastigotes. The recombinant A2 antigen plus saponin conferred about 40% protection against infection by this challenge system and has been registered in Brazil as a canine vaccine (LeishTec(®)). An increasing number of efficacy studies have privileged the use of natural challenge consisting in the long-term exposure of vaccinated dogs in endemic settings (Phase III). A 2-year field model including regular assessments by a set of standard diagnostic markers useful for an accurate infection staging has been developed. Again, most of the vaccines tested by this system, which included several antigen categories and adjuvants, failed to protect against infection and disease. Only two vaccines, consisting of parasite purified fractions with saponin derivative adjuvants, showed to confer significant protection against disease and death under natural conditions, and have been registered as canine vaccines: FML-QuilA (Leishmune(®)) in Brazil, and LiESP/QA-21 (CaniLeish(®)) in Europe.
authors.affiliation: Unit of Vector-borne Diseases and International Health, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy. Electronic address: luigi.gradoni@iss.it.
authors.forename: Luigi
authors.initials: L
authors.lastname: Gradoni
mesh_terms: D000818:Animals; D000953:Antigens, Protozoan / Q000276:immunology; D004283:Dog Diseases / Q000276:immunology / Q000517:prevention & control*; D004285:Dogs; D007111:Immunity, Cellular / Q000276:immunology; D018314:Leishmania infantum / Q000276:immunology*; D054332:Leishmaniasis Vaccines; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000517:prevention & control* / Q000662:veterinary*
chemical_list: D000953:Antigens, Protozoan; D054332:Leishmaniasis Vaccines
keywords: Canine leishmaniasis; Leishmania infantum; Vaccines